NFE2L2 and metabolic dysfunction-associated steatohepatitis: We have shown that mitochondria- and NOX4-derived ROS drive NFE2L2 antioxidant defense in hepatocytes to limit the oxidative damage of macromolecules, the development of insulin resistance, and the progression to NASH and fibrosis.